{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:48:14Z","timestamp":1740138494238,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"major scientific and technological innovation projects of the Shandong Province of China","award":["2019JZZY011018"],"award-info":[{"award-number":["2019JZZY011018"]}]},{"name":"Yantai Science and Technology Plan Project of China","award":["2019MSGY133"],"award-info":[{"award-number":["2019MSGY133"]}]},{"DOI":"10.13039\/501100018553","name":"Science and Technology Plan Project of Wenzhou, China","doi-asserted-by":"publisher","award":["2019YD004"],"award-info":[{"award-number":["2019YD004"]}],"id":[{"id":"10.13039\/501100018553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biotechnol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12033-022-00615-9","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T13:03:06Z","timestamp":1670677386000},"page":"1253-1262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction of Lentiviral Vector for miR-217 Overexpression and Knockdown and Its Effect on CML"],"prefix":"10.1007","volume":"65","author":[{"given":"Xin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9053","authenticated-orcid":false,"given":"Chengming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"615_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5189549","author":"J Xu","year":"2020","unstructured":"Xu, J., Wu, M., Sun, Y., Zhao, H., Wang, Y., & Gao, J. (2020). Identifying dysregulated lncRNA-associated ceRNA network biomarkers in CML based on dynamical network biomarkers. BioMed Research International. https:\/\/doi.org\/10.1155\/2020\/5189549","journal-title":"BioMed Research International"},{"issue":"12","key":"615_CR2","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","volume":"4","author":"C Vener","year":"2020","unstructured":"Vener, C., Banzi, R., Ambrogi, F., Ferrero, A., Saglio, G., Pravettoni, G., & Sant, M. (2020). First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: A systematic review and meta-analysis. Blood Advances, 4(12), 2723\u20132735. https:\/\/doi.org\/10.1182\/bloodadvances.2019001329","journal-title":"Blood Advances"},{"issue":"1","key":"615_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11899-020-00560-x","volume":"15","author":"D Gustafson","year":"2020","unstructured":"Gustafson, D., Fish, J. E., Lipton, J. H., & Aghel, N. (2020). Mechanisms of cardiovascular toxicity of BCR-ABL1 tyrosine kinase inhibitors in chronic myelogenous leukemia. Current Hematologic Malignancy Reports, 15(1), 20\u201330. https:\/\/doi.org\/10.1007\/s11899-020-00560-x","journal-title":"Current Hematologic Malignancy Reports"},{"issue":"6","key":"615_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3892\/etm.2020.9276","volume":"20","author":"N Wang","year":"2020","unstructured":"Wang, N., Mi, M., Wei, X., & Sun, C. (2020). Circadian clock gene Period2 suppresses human chronic myeloid leukemia cell proliferation. Experimental and Therapeutic Medicine, 20(6), 147. https:\/\/doi.org\/10.3892\/etm.2020.9276","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"1","key":"615_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0092-8674(02)00961-3","volume":"111","author":"L Fu","year":"2002","unstructured":"Fu, L., Pelicano, H., Liu, J., Huang, P., & Lee, C. (2002). The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell, 111(1), 41\u201350. https:\/\/doi.org\/10.1016\/s0092-8674(02)00961-3","journal-title":"Cell"},{"issue":"10","key":"615_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/mc.20198","volume":"45","author":"M-C Shih","year":"2006","unstructured":"Shih, M.-C., Yeh, K.-T., Tang, K.-P., Chen, J.-C., & Chang, J.-G. (2006). Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Molecular Carcinogenesis, 45(10), 732\u2013740.","journal-title":"Molecular Carcinogenesis"},{"issue":"6","key":"615_CR7","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1700\/1778.19292","volume":"100","author":"F Wang","year":"2014","unstructured":"Wang, F., Luo, Y., Li, C., & Chen, L. (2014). Correlation between deregulated expression of PER2 gene and degree of glioma malignancy. Tumori, 100(6), e266\u2013e272. https:\/\/doi.org\/10.1700\/1778.19292","journal-title":"Tumori"},{"issue":"15","key":"615_CR8","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.7150\/jca.21064","volume":"8","author":"J Samulin Erdem","year":"2017","unstructured":"Samulin Erdem, J., Skare, \u00d8., Petersen-\u00d8verleir, M., Not\u00f8, H. \u00d8., Lie, J.-A.S., Reszka, E., Pep\u0142o\u0144ska, B., & Zienolddiny, S. (2017). Mechanisms of breast cancer in shift workers: dna methylation in five core circadian genes in nurses working night shifts. Journal of Cancer, 8(15), 2876\u20132884. https:\/\/doi.org\/10.7150\/jca.21064","journal-title":"Journal of Cancer"},{"issue":"12","key":"615_CR9","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/j.1349-7006.2006.00331.x","volume":"97","author":"M-Y Yang","year":"2006","unstructured":"Yang, M.-Y., Chang, J.-G., Lin, P.-M., Tang, K.-P., Chen, Y.-H., Lin, H.Y.-H., Liu, T. C., Hsiao, H. H., Liu, Y. C., & Lin, S.-F. (2006). Downregulation of circadian clock genes in chronic myeloid leukemia: Alternative methylation pattern of hPER3. Cancer Science, 97(12), 1298\u20131307.","journal-title":"Cancer Science"},{"issue":"3","key":"615_CR10","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s11033-021-07027-z","volume":"49","author":"H Jiang","year":"2022","unstructured":"Jiang, H., Yang, X., Mi, M., Wei, X., Wu, H., Xin, Y., Jiao, L., Sun, S., & Sun, C. (2022). Development and performance evaluation of TaqMan real-time fluorescence quantitative methylation specific PCR for detecting methylation level of PER2. Molecular Biology Reports, 49(3), 2097\u20132105. https:\/\/doi.org\/10.1007\/s11033-021-07027-z","journal-title":"Molecular Biology Reports"},{"issue":"11","key":"615_CR11","doi-asserted-by":"publisher","first-page":"7587","DOI":"10.1007\/s11033-021-06751-w","volume":"48","author":"H Jiang","year":"2021","unstructured":"Jiang, H., Yang, X., Mi, M., Wei, X., Wu, H., Xin, Y., & Sun, C. (2021). PER2: A potential molecular marker for hematological malignancies. Molecular Biology Reports, 48(11), 7587\u20137595. https:\/\/doi.org\/10.1007\/s11033-021-06751-w","journal-title":"Molecular Biology Reports"},{"issue":"2","key":"615_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118101","volume":"10","author":"L Xia","year":"2015","unstructured":"Xia, L., Ma, S., Zhang, Y., Wang, T., Zhou, M., Wang, Z., & Zhang, J. (2015). Daily variation in global and local DNA methylation in mouse livers. PLoS ONE, 10(2), e0118101. https:\/\/doi.org\/10.1371\/journal.pone.0118101","journal-title":"PLoS ONE"},{"issue":"5","key":"615_CR13","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1002\/jcp.27486","volume":"234","author":"K Saliminejad","year":"2019","unstructured":"Saliminejad, K., Khorram Khorshid, H. R., Soleymani Fard, S., & Ghaffari, S. H. (2019). An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. Journal of Cellular Physiology, 234(5), 5451\u20135465. https:\/\/doi.org\/10.1002\/jcp.27486","journal-title":"Journal of Cellular Physiology"},{"key":"615_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev-pathol-012513-104715","volume":"9","author":"G Di Leva","year":"2014","unstructured":"Di Leva, G., Garofalo, M., & Croce, C. M. (2014). MicroRNAs in cancer. Annual review of pathology, 9, 287\u2013314. https:\/\/doi.org\/10.1146\/annurev-pathol-012513-104715","journal-title":"Annual review of pathology"},{"issue":"8","key":"615_CR15","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.1002\/jcp.28058","volume":"234","author":"H Mollaei","year":"2019","unstructured":"Mollaei, H., Safaralizadeh, R., & Rostami, Z. (2019). MicroRNA replacement therapy in cancer. Journal of Cellular Physiology, 234(8), 12369\u201312384. https:\/\/doi.org\/10.1002\/jcp.28058","journal-title":"Journal of Cellular Physiology"},{"issue":"30","key":"615_CR16","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1038\/sj.onc.1210228","volume":"26","author":"AE Szafranska","year":"2007","unstructured":"Szafranska, A. E., Davison, T. S., John, J., Cannon, T., Sipos, B., Maghnouj, A., Labourier, E., & Hahn, S. A. (2007). MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene, 26(30), 4442\u20134452.","journal-title":"Oncogene"},{"key":"615_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/biom11050639","author":"C Panebianco","year":"2021","unstructured":"Panebianco, C., Trivieri, N., Villani, A., Terracciano, F., Latiano, T. P., Potenza, A., Perri, F., Binda, E., & Pazienza, V. (2021). Improving gemcitabine sensitivity in pancreatic cancer cells by restoring miRNA-217 levels. Biomolecules. https:\/\/doi.org\/10.3390\/biom11050639","journal-title":"Biomolecules"},{"key":"615_CR18","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2021.4859","author":"J Yan","year":"2021","unstructured":"Yan, J., Fang, T., Zhang, M., & Zhou, Q. (2021). LINC00467 facilitates osteosarcoma progression by sponging miR-217 to regulate KPNA4 expression. International Journal of Molecular Medicine. https:\/\/doi.org\/10.3892\/ijmm.2021.4859","journal-title":"International Journal of Molecular Medicine"},{"key":"615_CR19","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20193176","author":"G Chen","year":"2020","unstructured":"Chen, G., Yang, Z., Feng, M., & Wang, Z. (2020). microRNA-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer. Bioscience Reports. https:\/\/doi.org\/10.1042\/BSR20193176"},{"issue":"9","key":"615_CR20","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00011-021-01494-7","volume":"70","author":"Z-M Huang","year":"2021","unstructured":"Huang, Z.-M., Wang, H., & Ji, Z.-G. (2021). Bladder mesenchymal stromal cell-derived exosomal miRNA-217 modulates bladder cancer cell survival through Hippo-YAP pathway. Inflammation Research: Official Journal of the EUROPEAN Histamine Research Society, 70(9), 959\u2013969. https:\/\/doi.org\/10.1007\/s00011-021-01494-7","journal-title":"Inflammation Research: Official Journal of the EUROPEAN Histamine Research Society"},{"key":"615_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.17179\/excli2021-3404","volume":"20","author":"T Mahdloo","year":"2021","unstructured":"Mahdloo, T., Sahami, P., Ramezani, R., Jafarinia, M., Goudarzi, H., & Babashah, S. (2021). Up-regulation of miR-155 potentiates CD34+ CML stem\/progenitor cells to escape from the growth-inhibitory effects of TGF-\u00df1 and BMP signaling. EXCLI Journal, 20, 748\u2013763. https:\/\/doi.org\/10.17179\/excli2021-3404","journal-title":"EXCLI Journal"},{"issue":"3","key":"615_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/cas.12339","volume":"105","author":"C Nishioka","year":"2014","unstructured":"Nishioka, C., Ikezoe, T., Yang, J., Nobumoto, A., Tsuda, M., & Yokoyama, A. (2014). Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors. Cancer Science, 105(3), 297\u2013307. https:\/\/doi.org\/10.1111\/cas.12339","journal-title":"Cancer Science"},{"issue":"40","key":"615_CR23","doi-asserted-by":"publisher","first-page":"15805","DOI":"10.1073\/pnas.0707628104","volume":"104","author":"M Fabbri","year":"2007","unstructured":"Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., Liu, S., Alder, H., Costinean, S., Fernandez-Cymering, C., Volinia, S., Guler, G., Morrison, C. D., Chan, K. K., Marcucci, G., Calin, G. A., Huebner, K., & Croce, C. M. (2007). MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 104(40), 15805\u201315810.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"615_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren, R. (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Reviews Cancer, 5(3), 172\u2013183.","journal-title":"Nature Reviews Cancer"},{"issue":"7","key":"615_CR25","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2013.096776","volume":"99","author":"S-H Kim","year":"2014","unstructured":"Kim, S.-H., Menon, H., Jootar, S., Saikia, T., Kwak, J.-Y., Sohn, S.-K., Park, J. S., Jeong, S. H., Kim, H. J., Kim, Y. K., Oh, S. J., & Kim, D.-W. (2014). Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica, 99(7), 1191\u20131196. https:\/\/doi.org\/10.3324\/haematol.2013.096776","journal-title":"Haematologica"},{"issue":"23","key":"615_CR26","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker, B. J., Guilhot, F., O\u2019Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., & Larson, R. A. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine, 355(23), 2408\u20132417.","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"615_CR27","doi-asserted-by":"publisher","first-page":"6970","DOI":"10.1021\/jacs.9b13159","volume":"142","author":"X Liu","year":"2020","unstructured":"Liu, X., Haniff, H. S., Childs-Disney, J. L., Shuster, A., Aikawa, H., Adibekian, A., & Disney, M. D. (2020). Targeted degradation of the oncogenic MicroRNA 17\u201392 cluster by structure-targeting ligands. Journal of the American Chemical Society, 142(15), 6970\u20136982. https:\/\/doi.org\/10.1021\/jacs.9b13159","journal-title":"Journal of the American Chemical Society"},{"issue":"4","key":"615_CR28","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3892\/or.2017.5924","volume":"38","author":"C Jiang","year":"2017","unstructured":"Jiang, C., Yu, M., Xie, X., Huang, G., Peng, Y., Ren, D., Lin, M., Liu, B., Liu, M., Wang, W., & Kuang, M. (2017). miR-217 targeting DKK1 promotes cancer stem cell properties via activation of the Wnt signaling pathway in hepatocellular carcinoma. Oncology Reports, 38(4), 2351\u20132359. https:\/\/doi.org\/10.3892\/or.2017.5924","journal-title":"Oncology Reports"},{"issue":"6","key":"615_CR29","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.3892\/or.2017.6036","volume":"38","author":"Q Chen","year":"2017","unstructured":"Chen, Q., Wang, P., Fu, Y., Liu, X., Xu, W., Wei, J., Gao, W., Jiang, K., Wu, J., & Miao, Y. (2017). MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma. Oncology Reports, 38(6), 3567\u20133573. https:\/\/doi.org\/10.3892\/or.2017.6036","journal-title":"Oncology Reports"},{"issue":"4","key":"615_CR30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1089\/cbr.2017.2394","volume":"34","author":"S He","year":"2019","unstructured":"He, S., Wang, Z., Tang, H., Dong, J., Qu, Y., & Lv, J. (2019). MiR-217 inhibits proliferation, migration, and invasion by targeting in osteosarcoma. Cancer Biotherapy & Radiopharmaceuticals, 34(4), 264\u2013270. https:\/\/doi.org\/10.1089\/cbr.2017.2394","journal-title":"Cancer Biotherapy & Radiopharmaceuticals"},{"issue":"2","key":"615_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12079-017-0410-x","volume":"12","author":"M Flum","year":"2018","unstructured":"Flum, M., Kleemann, M., Schneider, H., Weis, B., Fischer, S., Handrick, R., & Otte, K. (2018). miR-217-5p induces apoptosis by directly targeting PRKCI, BAG3, ITGAV and MAPK1 in colorectal cancer cells. Journal of Cell Communication and Signaling, 12(2), 451\u2013466. https:\/\/doi.org\/10.1007\/s12079-017-0410-x","journal-title":"Journal of Cell Communication and Signaling"}],"container-title":["Molecular Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-022-00615-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12033-022-00615-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-022-00615-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T07:18:35Z","timestamp":1689578315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12033-022-00615-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s12033-022-00615-9","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1073-6085","1559-0305"],"issn-type":[{"type":"print","value":"1073-6085"},{"type":"electronic","value":"1559-0305"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"4 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Participation"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}